Search

Valentina Perrone,1 Elisa Giacomini,1 Margherita Andretta,2 Loredana Arenare,3 Maria Rosaria Cillo,4 Marisa Latini,5 Alessandra Mecozzi,6 Romina Pagliaro,5 Adriano Vercellone,7 Luca Degli Esposti1 1CliCon S.r.l. Health, Economics & Outcomes Research, Bologna, Italy; 2UOC Assistenza Farmaceutica Territoriale, Azienda ULSS 8 Berica, Vicenza, Italy; 3UOC Farmaceutica e Territoriale e Integrativa– Asl Latina, Latina, Italy; 4Pharmaceutical Department Local Health Unit (LHU) Salerno, Salerno, Italy; 5U.O.C. Farmaceutica Territoriale – Asl Roma 5, Roma, Italy; 6UOC Farmacia SE/CTO Asl Roma 2, Roma, Italy; 7Department of Pharmacy, Local Health Unit (LHU) Naples 3 South, Napoli, ItalyCorrespondence: Valentina PerroneCliCon S.r.l. Health, Economics & Outcomes Research, via Murri, Bologna, 9 - 40137, ItalyTel +39 0544 38393Fax +39 0544 212699Email valentina.perrone@clicon.itPurpose: To date, litte evidence is reported about the real-life dosage of tyrosine kinase inhibitors prescribed in Italy. The present observational retrospective study aimed to evaluate the mean daily dose of nilotinib prescribed as first- and second-line therapy among patients suffering from chronic myeloid leukemia (CML) in settings of clinical practice in Italy.Patients and Methods: Data were obtained from the administrative databases of a sample of Italian entities. All adult patients prescribed nilotinib were included from January 2013 to December 2016 if they were using it as first-line and from January 2015 to December 2018 as second-line therapy. The mean daily dose was calculated considering the dosage between first and last nilotinib prescription date or last BCR/ABL test date.Results: Among CML patients treated with nilotinib as first-line (N=87), the mean daily dose of nilotinib was 500.5 mg during a mean treatment duration of 798.9 days and of 498.54 mg considering the last determination of BCR/ABL test (mean duration of 811 days). A total of 103 CML patien